Reading the presentation, I was reminded of the Arrowhead Research concerning homing peptides:
http://www.arrowheadresearch.com/technology/homing-peptides
Delivery of canonical (and especially certain classes of non-canonical) siRNA is a very big business.
This could be an "market disruptive" development that PYC could exploit.
Silencing siRNA (over a protein class) could lead the way for targetted therapeutics for Phylomers (silencing over a protein "phase").
Hence there is potential for PYC to participate in markets around siRNA delivery - which is currently a very lucrative place to be.
Reading the presentation, I was reminded of the Arrowhead...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.015(1.08%) |
Mkt cap ! $819.4M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.42 | $1.35 | $213.5K | 154.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5119 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 1450 | 3 |
View Market Depth
| Last trade - 13.46pm 22/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |